Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
May 11 2022 - 6:00PM
Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced
the appointment of cancer immunotherapy leader Jill
O’Donnell-Tormey, Ph.D., to its Board of Directors. Dr.
O’Donnell-Tormey will also serve on the Nominating and Corporate
Governance Committee of the Board of Directors.
Dr. O’Donnell-Tormey is the Chief Executive Officer
and Director of Scientific Affairs of the Cancer Research Institute
(“CRI”), a nonprofit organization dedicated exclusively to
advancing immunotherapy to treat, control and cure all cancers. She
joined the organization in 1987 and has been Chief Executive
Officer since 1993. As a recognized leader and advocate for cancer
immunotherapy, Dr. O’Donnell-Tormey has spearheaded programs at CRI
designed to identify and advance promising combination
immunotherapies as well as facilitate global coordination of
clinical research initiatives across academia and industry. Dr.
O’Donnell-Tormey serves on the boards of The City University of New
York (“CUNY”), Richmond University Medical Center, and the Staten
Island Foundation.
“I am excited to welcome Dr. Jill O’Donnell-Tormey to the
Coherus Board of Directors. Under her leadership and strategic
direction, the Cancer Research Institute has grown to play a key
role across the changing landscape of cancer immunology, pioneering
and driving advancements in the field,” said Denny Lanfear, CEO of
Coherus. “Jill’s experience and insights will be a perfect
complement to our Board as we continue to advance the development
of innovative cancer immunotherapies and build a leading
immuno-oncology franchise.”
“Translating promising science into cancer
treatments that can change patients' lives is at the core of CRI’s
mission. Next-generation immuno-oncology agents and combinations
can take us to the next stage of significantly improved outcomes
for patients,” said Dr. O’Donnell-Tormey. “I am excited to join the
Coherus Board of Directors and to help the company advance its goal
of delivering new immuno-oncology medicines to patients.”
Dr. O’Donnell-Tormey served as a research associate
in the department of medicine at Cornell University Medical College
and as a postdoctoral fellow in the laboratory of cellular
physiology and immunology at The Rockefeller University. She holds
a Doctor of Philosophy in cell biology from the SUNY Downstate
Medical Center and earned a Bachelor of Science in chemistry from
Fairleigh Dickinson University.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company building
a leading immuno-oncology franchise funded with cash generated by
its diversified portfolio of FDA-approved products. In 2021,
Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the
United States and Canada. Coherus plans to resubmit a BLA
for toripalimab for the treatment of advanced nasopharyngeal
carcinoma by mid-summer 2022. Toripalimab is also being evaluated
in pivotal clinical trials for the treatment of rare and highly
prevalent cancers.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of
Neulasta® in the United States, and expects to launch the
FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh)
in the United States in 2023. The FDA is currently
reviewing the biologics license application for CIMERLI™
(ranibizumab-ranq), a biosimilar of Lucentis®, with a target action
date of August 2022.
Forward-Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements regarding Coherus’ ability to build
its immuno-oncology franchise to achieve a leading market position
and execute on its strategy; Coherus’ ability to generate cash;
Coherus’ investment plans; Coherus’ expectations for the launch
date of YUSIMRY™ and the launch date or action date of other
products; Coherus’ plans to resubmit a BLA for toripalimab; and the
ability of Coherus to deliver new immuno-oncology medicines to
patients that result in improved outcomes.
Such forward-looking statements involve substantial risks and
uncertainties that could cause Coherus’ actual results, performance
or achievements to differ significantly from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties inherent in the clinical
drug development process; risks relating to the COVID-19 pandemic;
risks related to our existing and potential collaboration partners;
risks of the drug development position of Coherus’ competitors; the
risks and uncertainties of the regulatory approval process,
including the speed of regulatory review, international aspects of
Coherus’ business, the need to schedule inspections
in China and the timing of Coherus’ regulatory filings;
the risk of FDA review issues; risks relating to the approval of
toripalimab, the risk of Coherus’ execution of its change in
strategy from a focus on biosimilars to a strategy using cash from
its portfolio to fund an immuno-oncology franchise; the risk that
Coherus is unable to complete commercial transactions and other
matters that could affect the availability or commercial potential
of Coherus’ drug candidates; and the risks and uncertainties of
litigation. All forward-looking statements contained in this press
release speak only as of the date of this press release. Coherus
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the significant risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Coherus’ business in general, see Coherus’ Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022,
filed with the Securities and Exchange Commission on May
5, 2022, including the section therein captioned “Risk Factors” and
in other documents Coherus files with the Securities and
Exchange Commission.
UDENYCA®, YUSIMRY™ and CIMERLI™, whether or not appearing in
large print or with the trademark symbol, are trademarks of
Coherus, its affiliates, related companies or its licensors or
joint venture partners, unless otherwise noted. Trademarks and
trade names of other companies appearing in this press release are,
to the knowledge of Coherus, the property of their respective
owners.
Coherus Contact Information:McDavid StilwellChief Financial
OfficerCoherus BioSciences, Inc.IR@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024